Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Transthyretin Amyloidosis (ATTR) is a progressive and severe orphan disease. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a type of transthyretin amyloidosis (ATTR) that affects the heart and leads to restrictive cardiomyopathy and progressive heart failure. It is generally a rare, underdiagnosed, life-threatening disease. The increasing incidence of transthyretin amyloid cardiomyopathy (ATTR-CM) among the aging population is expected to boost the transthyretin amyloid cardiomyopathy (ATTR-CM) market growth. For instance, according to an article published by the World Heart Federation in August 2019, wild- form of transthyretin amyloid cardiomyopathy (ATTR-CM) is a more common type and usually affects men after the age of 60, and hereditary transthyretin amyloidosis (hATTR) occurs in people in their 50s and 60s.
The global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market is estimated to be valued at US$ 748.80 million in 2020 and is expected to exhibit a CAGR of 31.1% during the forecast period (2020-2027).
Figure 1. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Share (%), by Region, 2020
-treatment-market-fig-1.png)
Ongoing research and development activities are expected to propel growth of the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.
Major players in the market are focused on research and development of transthyretin amyloid cardiomyopathy (ATTR-CM) treatment, which is expected to boost the market growth during the forecast period. For instance, in January 2020, Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc., collaboratively initiated CARDIO-TTRansform Phase III cardiovascular outcomes study for AKCEA-TTR-LRx in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
However, lack of diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) is expected to hinder the market growth. For instance, according to an article published by the Amyloidosis Foundation, in 2016, among the two type of transthyretin amyloid cardiomyopathy (ATTR-CM), wild type transthyretin amyloidosis (wtATTR) is difficult to diagnose than hereditary transthyretin amyloidosis (hATTR) as there is no family history or genetic marker for the disease.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Report Coverage
Report Coverage |
Details |
Base Year: |
2019 |
Market Size in 2020: |
US$ 748.80 Mn |
Historical Data for: |
2016 to 2019 |
Forecast Period: |
2020 to 2027 |
Forecast Period 2020 to 2027 CAGR: |
31.1% |
2027 Value Projection: |
US$ 4,984.58 Mn |
Geographies covered: |
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
|
Segments covered: |
- By Type: Hereditary Transthyretin Amyloidosis (hATTR), Wild Type Transthyretin Amyloidosis (wtATTR).
- By Drug Type: Transthyretin Stabilizers, Nonsteroidal anti-inflammatory drugs (NSAID), RNAi therapy, Others.
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
|
Companies covered: |
Pfizer Inc., GlaxoSmithKline Plc., Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., and Corino Therapeutics, Inc.
|
Growth Drivers: |
- The rising incidence of transthyretin amyloid cardiomyopathy (ATTR-CM)
- Ongoing research and development of transthyretin amyloid cardiomyopathy (ATTR-CM) treatments
|
Restraints & Challenges: |
- Lack of diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM)
- Lack of awareness about transthyretin amyloid cardiomyopathy (ATTR-CM)
|
Figure 2. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Share (%), by Type 2020
-treatment-market-fig-2.png)
Ongoing clinical trials for transthyretin amyloid cardiomyopathy (ATTR-CM) in North America are expected to boost the market growth.
North America is expected to hold dominant position in the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market owing to the ongoing clinical trials for transthyretin amyloid cardiomyopathy (ATTR-CM) in the region. For instance, in November 2020, Intellia Therapeutics, Inc. announced that the first patient has been treated with NTLA-2001, CRISPR/Cas9 technology, which the company is developing as a single-course, potentially curative therapy for transthyretin amyloidosis (ATTR).
Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) pandemic and resulting lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. Private healthcare is one such sector, which has been impacted significantly by the COVID-19 pandemic.
The lockdown in various countries have placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products, and affected growth of healthcare businesses of various companies across the globe.
As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market during the forecast period.
Key Players
Major players operating in the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., and Corino Therapeutics, Inc. among others.